German biotech firm Tubulis has raised €308 million in a record-breaking Sequence C funding spherical, marking the most important Sequence C ever closed by a European biotech and the most important financing for a personal antibody-drug conjugate (ADC) developer worldwide. The spherical was led by Venrock Healthcare Capital Companions, with participation from Wellington Administration and Ascenta Capital, alongside current traders together with Nextech Make investments, EQT Life Sciences, Frazier Life Sciences, Andera Companions, Deep Monitor Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Companions, and HTGF.
Based in Munich, Tubulis specialises in creating uniquely matched ADCs that mix antibodies with potent medication to focus on and destroy most cancers cells with excessive precision. The brand new funding will speed up the medical growth of its lead candidate, TUB-040, which targets NaPi2b, an antigen overexpressed in ovarian and lung cancers. At the moment below analysis in a Section I/IIa examine, TUB-040 acquired Quick Monitor designation from the U.S. FDA in 2024.
The contemporary capital may also advance Tubulis’ broader pipeline, together with TUB-030 and a number of preclinical programmes, in addition to broaden its proprietary ADC platform applied sciences. These improvements goal to unlock new therapeutic prospects and enhance outcomes for sufferers with stable tumours.
“This landmark financing spherical displays the deep conviction these international healthcare traders have in Tubulis and the disruptive potential of our ADC platforms,” mentioned Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. “With TUB-040 progressing within the clinic and first knowledge to be shared in a late-breaking oral presentation at ESMO, we’re able to broaden into earlier remedy strains, whereas persevering with to innovate throughout our pipeline and know-how platforms. The brand new funding empowers us to execute on our imaginative and prescient of making really differentiated antibody-drug conjugates which might be tailor-made to the biology of stable tumours and may ship superior therapeutic worth to sufferers.”
HTGF (Excessive-Tech Gründerfonds), considered one of Tubulis’ earliest backers, renewed and expanded its dedication on this spherical. The investor co-led Tubulis’ Sequence A in 2020 and has supported the corporate from idea to medical growth, underlining Germany’s energy as a biotech innovation hub and its potential to mobilise non-public capital for capital-intensive applied sciences.
“HTGF was considered one of our earliest traders and supported us in shaping Tubulis throughout its early life. Their renewed dedication on this spherical displays the continued partnership and shared perception in our mission to broaden the therapeutic potential of ADCs for sufferers worldwide,” mentioned Dr. Dominik Schumacher, CEO and Co-founder of Tubulis.
Dr. Frank Hensel, Principal at HTGF, added: “Our relationship with Tubulis has at all times been constructed on belief and a shared ambition to redefine oncology remedy. This newest spherical, supported by main international traders, validates the energy of the platform and the workforce. We’re proud to proceed backing Tubulis because it enters a pivotal part of medical growth.”
Dr. Achim Plum, Managing Director at HTGF, mentioned: “Tubulis’ Sequence C demonstrates that even extremely capital-intensive, disruptive applied sciences can appeal to the non-public funding wanted to convey cutting-edge therapies to sufferers. For us at HTGF, Tubulis is a primary instance of how we function: we interact very early, usually earlier than an organization is based, and construct trusted relationships with distinctive groups. This story displays our perception in scientific excellence, entrepreneurial imaginative and prescient, and the affect that may be achieved when each come collectively. Congratulations to your complete Tubulis workforce on this excellent success.”
Tubulis’ breakthrough ADC applied sciences have positioned it as considered one of Europe’s most promising biotech gamers. By combining world-class science, medical progress, and international investor confidence, the corporate continues to advance its mission of increasing the therapeutic potential of ADCs for most cancers sufferers worldwide.
